Regeneron director Sing proposes $960K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Regeneron Pharmaceuticals, Inc. director George L. Sing filed notice of a proposed sale of 1,000 common shares, with an approximate sale date of November 16, 2026 and an aggregate market value of $960,264.40. The notice lists the shares as acquired from the issuer through a private acquisition for cash on April 9, 1991. It also reports that Sing sold 21,129 common shares on November 2, 2026, for gross proceeds of $20,376,359.76.
Key Figures
Key Terms
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.